Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China
Background:We aimed to examine the evolution of blood lipids and compare the risk of dyslipidemia between antiretroviral-naive people living with HIV who received tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and efavirenz (EFV) (TDF + 3TC + EFV) and those who received coformulated elvitegr...
Gespeichert in:
| Veröffentlicht in: | Journal of acquired immune deficiency syndromes (1999) 2022-10, Vol.91 (S1), p.S8-S15 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S15 |
|---|---|
| container_issue | S1 |
| container_start_page | S8 |
| container_title | Journal of acquired immune deficiency syndromes (1999) |
| container_volume | 91 |
| creator | Sun, Liqin He, Yun Xu, Liumei Zhao, Fang Zhou, Yang Zhang, Lukun Peng, Qiaoli Zhang, Haitao Zhang, Qiuyue Cao, Tingzhi Song, Ying Wang, Siyuan Rao, Man Jia, Xinyun Liu, Xiaoning Zhou, Jing Ju, Bin Wang, Hui Liu, Jiaye |
| description | Background:We aimed to examine the evolution of blood lipids and compare the risk of dyslipidemia between antiretroviral-naive people living with HIV who received tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and efavirenz (EFV) (TDF + 3TC + EFV) and those who received coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF).Methods:We retrospectively reviewed the medical records of 2343 antiretroviral-naive people living with HIV who initiated TDF + 3TC + EFV or E/C/F/TAF. A propensity score matching method was used to compare longitudinal changes of blood lipids between the 2 groups.Results:By using 1:3 matching ratio, we included 253 and 91 matched patients in TDF + 3TC + EFV group and E/C/F/TAF group, respectively. The levels of total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol were higher in E/C/F/TAF group than those in TDF + 3TC + EFV group at 3, 6, 9, and 12 months (Wilcoxon test, all Ps < 0.05), except for high-density lipoprotein cholesterol at 9 and 12 months. The cumulative rates of hypercholesterolemia, hypertriglyceridemia, and high LDL-C in PLWH with normal lipid levels in E/C/F/TAF group were higher than those in TDF + 3TC + EFV group (hypercholesterolemia, 59.7% vs 21.5%, P < 0.001; hypertriglyceridemia, 69.5% vs 46.3%, P < 00.001; and high LDL-C, 41.5% vs 14.2%, P < 0.001). Multivariate analysis showed treatment with E/C/F/TAF was associated with a significantly higher risk of hypercholesterolemia [adjusted hazard ratio (HR), 4.12; 95% confidence interval (CI): 2.65 to 6.41], hypertriglyceridemia (adjusted HR, 1.69; 95% CI: 1.18 to 2.43), and high LDL-C (adjusted HR, 4.60; 95% CI: 2.66 to 7.97).Conclusions:We concluded that treatment with E/C/F/TAF resulted in higher risks of dyslipidemia compared with TDF + 3TC + EFV. |
| doi_str_mv | 10.1097/QAI.0000000000003040 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2713308741</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2712825494</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4032-19e007478b4923d0b7dfb05585cff10cf5962bf20bc111a356912d2b4fd8f3b23</originalsourceid><addsrcrecordid>eNptkc2O0zAUhSMEEkPhDVhciQ2LZvBfmmRZdTq0UsWfBlhGTmI3d8axi-10GN6Yt8BlkEAjvLGv_Z2jI58se0nJOSV1-ebjcntO_lmcCPIoO6O1EHlZVeJxOhesyAXlxdPsWQjXhNCFEPVZ9nOD-0F5-IThBpyGi7tg8IC9GlHCV4wDrJx2fpyMjKqHtTliVHsvj-jn6anFDkOUcQ7rMfo0RNmiVXOQtocrZZM2kbA0Uisrx-QLcZAW1vrkoOyPOezS9XHq_6O6wOAO3n1HA5fTKH1KAMvR2T0sbUzq6E-YNPk7iUcFH5Q7GAU7PGJCfmffbL8AWlgNaOXz7ImWJqgXf_ZZ9vlyfbXa5Lv3b7er5S7vBOEsp7UipBRl1Yqa8Z60Za9bUhRV0WlNSaeLesFazUjbUUolLxY1ZT1rhe4rzVvGZ9nre98U_dukQmxGDJ0yRlrlptCwknJOqjKVMctePUCv3eRtSneiWMUKUYtEiXuq8y4Er3Rz8Ji-466hpDn136T-m4f9_5XdOhOVDzdmulW-GZQ0cUg4ZQvORc4IYzRNND8pGf8FSly1-g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2712825494</pqid></control><display><type>article</type><title>Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China</title><source>Journals@Ovid LWW Legacy Archive</source><source>Free E- Journals</source><creator>Sun, Liqin ; He, Yun ; Xu, Liumei ; Zhao, Fang ; Zhou, Yang ; Zhang, Lukun ; Peng, Qiaoli ; Zhang, Haitao ; Zhang, Qiuyue ; Cao, Tingzhi ; Song, Ying ; Wang, Siyuan ; Rao, Man ; Jia, Xinyun ; Liu, Xiaoning ; Zhou, Jing ; Ju, Bin ; Wang, Hui ; Liu, Jiaye</creator><creatorcontrib>Sun, Liqin ; He, Yun ; Xu, Liumei ; Zhao, Fang ; Zhou, Yang ; Zhang, Lukun ; Peng, Qiaoli ; Zhang, Haitao ; Zhang, Qiuyue ; Cao, Tingzhi ; Song, Ying ; Wang, Siyuan ; Rao, Man ; Jia, Xinyun ; Liu, Xiaoning ; Zhou, Jing ; Ju, Bin ; Wang, Hui ; Liu, Jiaye</creatorcontrib><description>Background:We aimed to examine the evolution of blood lipids and compare the risk of dyslipidemia between antiretroviral-naive people living with HIV who received tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and efavirenz (EFV) (TDF + 3TC + EFV) and those who received coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF).Methods:We retrospectively reviewed the medical records of 2343 antiretroviral-naive people living with HIV who initiated TDF + 3TC + EFV or E/C/F/TAF. A propensity score matching method was used to compare longitudinal changes of blood lipids between the 2 groups.Results:By using 1:3 matching ratio, we included 253 and 91 matched patients in TDF + 3TC + EFV group and E/C/F/TAF group, respectively. The levels of total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol were higher in E/C/F/TAF group than those in TDF + 3TC + EFV group at 3, 6, 9, and 12 months (Wilcoxon test, all Ps < 0.05), except for high-density lipoprotein cholesterol at 9 and 12 months. The cumulative rates of hypercholesterolemia, hypertriglyceridemia, and high LDL-C in PLWH with normal lipid levels in E/C/F/TAF group were higher than those in TDF + 3TC + EFV group (hypercholesterolemia, 59.7% vs 21.5%, P < 0.001; hypertriglyceridemia, 69.5% vs 46.3%, P < 00.001; and high LDL-C, 41.5% vs 14.2%, P < 0.001). Multivariate analysis showed treatment with E/C/F/TAF was associated with a significantly higher risk of hypercholesterolemia [adjusted hazard ratio (HR), 4.12; 95% confidence interval (CI): 2.65 to 6.41], hypertriglyceridemia (adjusted HR, 1.69; 95% CI: 1.18 to 2.43), and high LDL-C (adjusted HR, 4.60; 95% CI: 2.66 to 7.97).Conclusions:We concluded that treatment with E/C/F/TAF resulted in higher risks of dyslipidemia compared with TDF + 3TC + EFV.</description><identifier>ISSN: 1525-4135</identifier><identifier>EISSN: 1944-7884</identifier><identifier>DOI: 10.1097/QAI.0000000000003040</identifier><language>eng</language><publisher>Hagerstown: JAIDS Journal of Acquired Immune Deficiency Syndromes</publisher><subject>Antiretroviral agents ; Antiretroviral drugs ; Blood ; Cholesterol ; Density ; Dyslipidemia ; Efavirenz ; Emtricitabine ; High density lipoprotein ; HIV ; Human immunodeficiency virus ; Hypercholesterolemia ; Hypertriglyceridemia ; Lamivudine ; Lipids ; Lipoproteins ; Low density lipoprotein ; Matching ; Medical records ; Metabolic disorders ; Multivariate analysis ; Risk ; Tenofovir ; Triglycerides</subject><ispartof>Journal of acquired immune deficiency syndromes (1999), 2022-10, Vol.91 (S1), p.S8-S15</ispartof><rights>JAIDS Journal of Acquired Immune Deficiency Syndromes</rights><rights>Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4032-19e007478b4923d0b7dfb05585cff10cf5962bf20bc111a356912d2b4fd8f3b23</citedby><cites>FETCH-LOGICAL-c4032-19e007478b4923d0b7dfb05585cff10cf5962bf20bc111a356912d2b4fd8f3b23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00126334-202210011-00002$$EHTML$$P50$$Gwolterskluwer$$H</linktohtml><link.rule.ids>314,776,780,4595,27901,27902,65206</link.rule.ids></links><search><creatorcontrib>Sun, Liqin</creatorcontrib><creatorcontrib>He, Yun</creatorcontrib><creatorcontrib>Xu, Liumei</creatorcontrib><creatorcontrib>Zhao, Fang</creatorcontrib><creatorcontrib>Zhou, Yang</creatorcontrib><creatorcontrib>Zhang, Lukun</creatorcontrib><creatorcontrib>Peng, Qiaoli</creatorcontrib><creatorcontrib>Zhang, Haitao</creatorcontrib><creatorcontrib>Zhang, Qiuyue</creatorcontrib><creatorcontrib>Cao, Tingzhi</creatorcontrib><creatorcontrib>Song, Ying</creatorcontrib><creatorcontrib>Wang, Siyuan</creatorcontrib><creatorcontrib>Rao, Man</creatorcontrib><creatorcontrib>Jia, Xinyun</creatorcontrib><creatorcontrib>Liu, Xiaoning</creatorcontrib><creatorcontrib>Zhou, Jing</creatorcontrib><creatorcontrib>Ju, Bin</creatorcontrib><creatorcontrib>Wang, Hui</creatorcontrib><creatorcontrib>Liu, Jiaye</creatorcontrib><title>Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China</title><title>Journal of acquired immune deficiency syndromes (1999)</title><description>Background:We aimed to examine the evolution of blood lipids and compare the risk of dyslipidemia between antiretroviral-naive people living with HIV who received tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and efavirenz (EFV) (TDF + 3TC + EFV) and those who received coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF).Methods:We retrospectively reviewed the medical records of 2343 antiretroviral-naive people living with HIV who initiated TDF + 3TC + EFV or E/C/F/TAF. A propensity score matching method was used to compare longitudinal changes of blood lipids between the 2 groups.Results:By using 1:3 matching ratio, we included 253 and 91 matched patients in TDF + 3TC + EFV group and E/C/F/TAF group, respectively. The levels of total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol were higher in E/C/F/TAF group than those in TDF + 3TC + EFV group at 3, 6, 9, and 12 months (Wilcoxon test, all Ps < 0.05), except for high-density lipoprotein cholesterol at 9 and 12 months. The cumulative rates of hypercholesterolemia, hypertriglyceridemia, and high LDL-C in PLWH with normal lipid levels in E/C/F/TAF group were higher than those in TDF + 3TC + EFV group (hypercholesterolemia, 59.7% vs 21.5%, P < 0.001; hypertriglyceridemia, 69.5% vs 46.3%, P < 00.001; and high LDL-C, 41.5% vs 14.2%, P < 0.001). Multivariate analysis showed treatment with E/C/F/TAF was associated with a significantly higher risk of hypercholesterolemia [adjusted hazard ratio (HR), 4.12; 95% confidence interval (CI): 2.65 to 6.41], hypertriglyceridemia (adjusted HR, 1.69; 95% CI: 1.18 to 2.43), and high LDL-C (adjusted HR, 4.60; 95% CI: 2.66 to 7.97).Conclusions:We concluded that treatment with E/C/F/TAF resulted in higher risks of dyslipidemia compared with TDF + 3TC + EFV.</description><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>Blood</subject><subject>Cholesterol</subject><subject>Density</subject><subject>Dyslipidemia</subject><subject>Efavirenz</subject><subject>Emtricitabine</subject><subject>High density lipoprotein</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Hypercholesterolemia</subject><subject>Hypertriglyceridemia</subject><subject>Lamivudine</subject><subject>Lipids</subject><subject>Lipoproteins</subject><subject>Low density lipoprotein</subject><subject>Matching</subject><subject>Medical records</subject><subject>Metabolic disorders</subject><subject>Multivariate analysis</subject><subject>Risk</subject><subject>Tenofovir</subject><subject>Triglycerides</subject><issn>1525-4135</issn><issn>1944-7884</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNptkc2O0zAUhSMEEkPhDVhciQ2LZvBfmmRZdTq0UsWfBlhGTmI3d8axi-10GN6Yt8BlkEAjvLGv_Z2jI58se0nJOSV1-ebjcntO_lmcCPIoO6O1EHlZVeJxOhesyAXlxdPsWQjXhNCFEPVZ9nOD-0F5-IThBpyGi7tg8IC9GlHCV4wDrJx2fpyMjKqHtTliVHsvj-jn6anFDkOUcQ7rMfo0RNmiVXOQtocrZZM2kbA0Uisrx-QLcZAW1vrkoOyPOezS9XHq_6O6wOAO3n1HA5fTKH1KAMvR2T0sbUzq6E-YNPk7iUcFH5Q7GAU7PGJCfmffbL8AWlgNaOXz7ImWJqgXf_ZZ9vlyfbXa5Lv3b7er5S7vBOEsp7UipBRl1Yqa8Z60Za9bUhRV0WlNSaeLesFazUjbUUolLxY1ZT1rhe4rzVvGZ9nre98U_dukQmxGDJ0yRlrlptCwknJOqjKVMctePUCv3eRtSneiWMUKUYtEiXuq8y4Er3Rz8Ji-466hpDn136T-m4f9_5XdOhOVDzdmulW-GZQ0cUg4ZQvORc4IYzRNND8pGf8FSly1-g</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Sun, Liqin</creator><creator>He, Yun</creator><creator>Xu, Liumei</creator><creator>Zhao, Fang</creator><creator>Zhou, Yang</creator><creator>Zhang, Lukun</creator><creator>Peng, Qiaoli</creator><creator>Zhang, Haitao</creator><creator>Zhang, Qiuyue</creator><creator>Cao, Tingzhi</creator><creator>Song, Ying</creator><creator>Wang, Siyuan</creator><creator>Rao, Man</creator><creator>Jia, Xinyun</creator><creator>Liu, Xiaoning</creator><creator>Zhou, Jing</creator><creator>Ju, Bin</creator><creator>Wang, Hui</creator><creator>Liu, Jiaye</creator><general>JAIDS Journal of Acquired Immune Deficiency Syndromes</general><general>Lippincott Williams & Wilkins Ovid Technologies</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7T5</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20221001</creationdate><title>Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China</title><author>Sun, Liqin ; He, Yun ; Xu, Liumei ; Zhao, Fang ; Zhou, Yang ; Zhang, Lukun ; Peng, Qiaoli ; Zhang, Haitao ; Zhang, Qiuyue ; Cao, Tingzhi ; Song, Ying ; Wang, Siyuan ; Rao, Man ; Jia, Xinyun ; Liu, Xiaoning ; Zhou, Jing ; Ju, Bin ; Wang, Hui ; Liu, Jiaye</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4032-19e007478b4923d0b7dfb05585cff10cf5962bf20bc111a356912d2b4fd8f3b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>Blood</topic><topic>Cholesterol</topic><topic>Density</topic><topic>Dyslipidemia</topic><topic>Efavirenz</topic><topic>Emtricitabine</topic><topic>High density lipoprotein</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Hypercholesterolemia</topic><topic>Hypertriglyceridemia</topic><topic>Lamivudine</topic><topic>Lipids</topic><topic>Lipoproteins</topic><topic>Low density lipoprotein</topic><topic>Matching</topic><topic>Medical records</topic><topic>Metabolic disorders</topic><topic>Multivariate analysis</topic><topic>Risk</topic><topic>Tenofovir</topic><topic>Triglycerides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sun, Liqin</creatorcontrib><creatorcontrib>He, Yun</creatorcontrib><creatorcontrib>Xu, Liumei</creatorcontrib><creatorcontrib>Zhao, Fang</creatorcontrib><creatorcontrib>Zhou, Yang</creatorcontrib><creatorcontrib>Zhang, Lukun</creatorcontrib><creatorcontrib>Peng, Qiaoli</creatorcontrib><creatorcontrib>Zhang, Haitao</creatorcontrib><creatorcontrib>Zhang, Qiuyue</creatorcontrib><creatorcontrib>Cao, Tingzhi</creatorcontrib><creatorcontrib>Song, Ying</creatorcontrib><creatorcontrib>Wang, Siyuan</creatorcontrib><creatorcontrib>Rao, Man</creatorcontrib><creatorcontrib>Jia, Xinyun</creatorcontrib><creatorcontrib>Liu, Xiaoning</creatorcontrib><creatorcontrib>Zhou, Jing</creatorcontrib><creatorcontrib>Ju, Bin</creatorcontrib><creatorcontrib>Wang, Hui</creatorcontrib><creatorcontrib>Liu, Jiaye</creatorcontrib><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sun, Liqin</au><au>He, Yun</au><au>Xu, Liumei</au><au>Zhao, Fang</au><au>Zhou, Yang</au><au>Zhang, Lukun</au><au>Peng, Qiaoli</au><au>Zhang, Haitao</au><au>Zhang, Qiuyue</au><au>Cao, Tingzhi</au><au>Song, Ying</au><au>Wang, Siyuan</au><au>Rao, Man</au><au>Jia, Xinyun</au><au>Liu, Xiaoning</au><au>Zhou, Jing</au><au>Ju, Bin</au><au>Wang, Hui</au><au>Liu, Jiaye</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China</atitle><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle><date>2022-10-01</date><risdate>2022</risdate><volume>91</volume><issue>S1</issue><spage>S8</spage><epage>S15</epage><pages>S8-S15</pages><issn>1525-4135</issn><eissn>1944-7884</eissn><abstract>Background:We aimed to examine the evolution of blood lipids and compare the risk of dyslipidemia between antiretroviral-naive people living with HIV who received tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and efavirenz (EFV) (TDF + 3TC + EFV) and those who received coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF).Methods:We retrospectively reviewed the medical records of 2343 antiretroviral-naive people living with HIV who initiated TDF + 3TC + EFV or E/C/F/TAF. A propensity score matching method was used to compare longitudinal changes of blood lipids between the 2 groups.Results:By using 1:3 matching ratio, we included 253 and 91 matched patients in TDF + 3TC + EFV group and E/C/F/TAF group, respectively. The levels of total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol were higher in E/C/F/TAF group than those in TDF + 3TC + EFV group at 3, 6, 9, and 12 months (Wilcoxon test, all Ps < 0.05), except for high-density lipoprotein cholesterol at 9 and 12 months. The cumulative rates of hypercholesterolemia, hypertriglyceridemia, and high LDL-C in PLWH with normal lipid levels in E/C/F/TAF group were higher than those in TDF + 3TC + EFV group (hypercholesterolemia, 59.7% vs 21.5%, P < 0.001; hypertriglyceridemia, 69.5% vs 46.3%, P < 00.001; and high LDL-C, 41.5% vs 14.2%, P < 0.001). Multivariate analysis showed treatment with E/C/F/TAF was associated with a significantly higher risk of hypercholesterolemia [adjusted hazard ratio (HR), 4.12; 95% confidence interval (CI): 2.65 to 6.41], hypertriglyceridemia (adjusted HR, 1.69; 95% CI: 1.18 to 2.43), and high LDL-C (adjusted HR, 4.60; 95% CI: 2.66 to 7.97).Conclusions:We concluded that treatment with E/C/F/TAF resulted in higher risks of dyslipidemia compared with TDF + 3TC + EFV.</abstract><cop>Hagerstown</cop><pub>JAIDS Journal of Acquired Immune Deficiency Syndromes</pub><doi>10.1097/QAI.0000000000003040</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1525-4135 |
| ispartof | Journal of acquired immune deficiency syndromes (1999), 2022-10, Vol.91 (S1), p.S8-S15 |
| issn | 1525-4135 1944-7884 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2713308741 |
| source | Journals@Ovid LWW Legacy Archive; Free E- Journals |
| subjects | Antiretroviral agents Antiretroviral drugs Blood Cholesterol Density Dyslipidemia Efavirenz Emtricitabine High density lipoprotein HIV Human immunodeficiency virus Hypercholesterolemia Hypertriglyceridemia Lamivudine Lipids Lipoproteins Low density lipoprotein Matching Medical records Metabolic disorders Multivariate analysis Risk Tenofovir Triglycerides |
| title | Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T02%3A45%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Higher%20Risk%20of%20Dyslipidemia%20With%20Coformulated%20Elvitegravir,%20Cobicistat,%20Emtricitabine,%20and%20Tenofovir%20Alafenamide%20than%20Efavirenz,%20Lamivudine,%20and%20Tenofovir%20Disoproxil%20Fumarate%20Among%20Antiretroviral-Naive%20People%20Living%20With%20HIV%20in%20China&rft.jtitle=Journal%20of%20acquired%20immune%20deficiency%20syndromes%20(1999)&rft.au=Sun,%20Liqin&rft.date=2022-10-01&rft.volume=91&rft.issue=S1&rft.spage=S8&rft.epage=S15&rft.pages=S8-S15&rft.issn=1525-4135&rft.eissn=1944-7884&rft_id=info:doi/10.1097/QAI.0000000000003040&rft_dat=%3Cproquest_cross%3E2712825494%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2712825494&rft_id=info:pmid/&rfr_iscdi=true |